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Colorectal cancer (CRC) development is a step-wise 
process initiated by the transformation of epithelial cells 
in the intestinal crypts, followed by the accumulation of 
multiple genetic events driving adenoma to carcinoma 
progression. In this way, genomic instability underlies 
the majority of CRCs and chromosomal alterations such 
as translocations, amplifications and deletions are 
frequently seen.  
In human, the gene encoding the intracellular sorting 
protein phosphofurin acidic cluster sorting protein-2 
(PACS-2) is located near the telomere at 14q32.33, a 
locus prone to allelic loss in sporadic CRC. Accor-
dingly, PACS-2 protein expression was found to be lost 
or greatly reduced in tumor tissue from approximately 
half the CRC patients analyzed [1]. Searching the 
Cancer Genome Atlas (http://cancergenome.nih. gov), 
Pacs2 is found mutated in 5% of CRC cases, with the 
two most frequent somatic mutations leading to inframe 
deletions. Also, Pacs2 was identified as one of 25 genes 
that can be used to distinguish different CRC stages [2].  
With the described correlations, the question arising is 
whether Pacs2 loss is a driver or passenger mutation in 
the development of CRC? To answer this question, 
depletion of pacs2 in mice is a useful experimental 
model. PACS-2-deficient mice do not develop spon-
taneous neoplastic lesions in the intestine, and we 
recently reported that inactivation of one allele of the 
APC gene (ApcMin) – a commonly used model of 
human colon cancer – in PACS-2-deficient mice had no 
apparent consequence for adenoma development [3]. 
Rather, mice lacking PACS-2 expression exhibit 
reduced activity of the epidermal growth factor receptor 
(EGFR) and lower proliferative index in the intestinal 
epithelium [4]. Likely explaining this observation, we 
previously showed that PACS-2 directs recycling of a 
disintegrin and metalloprotease (ADAM)17 towards the 
cell surface to sustain shedding of EGFR ligands and 
consequent EGFR activation [4]. Ligand-induced EGFR 
signaling stimulates cell proliferation, differentiation, 
and survival and it plays an important, yet complex role 
in the development and progression of CRC – e.g. 
deletion of EGFR from myeloid cells, but not intestinal 
epithelial cells protects mice from inflammation-
induced intestinal cancer and ApcMin-dependent intes-
tinal tumorigenesis [5]. ADAM17 is required for EGFR-
induced intestinal tumors, apparently by shedding  EGFR 
ligands to activate  EGFR-dependent  interleukin (IL)-6 








synthesis in colonic myloid cells, which via IL-6 trans-
signaling induces epithelial tumor formation [6].   
The explanation why PACS-2 loss has no apparent 
effect on intestinal tumor formation may lie in the 
complex roles of PACS-2 as a phosphorylation-state 
dependent molecular switch that mediates either anti-
apoptotic or pro-apoptotic signaling [7]. In response to 
DNA damage, Akt-phosphorylated PACS-2 promotes 
pro-survival signaling; it binds the DNA damage kinase 
ATM to promote the NF-kB-dependent induction of 
anti-apoptotic Bcl-xL and it inhibits the class III 
deacetylase SIRT1 to promote the p53-dependent induc-
tion of cyclin dependent kinase inhibitor p21 
(CDKN1A). By contrast, the death ligand TRAIL trig-
gers dephosphorylation of PACS-2, which switches the 
multi-functional protein to become a pro-apoptotic 
effector. Dephosphorylated PACS-2 shuttles the BH3-
only proteins Bid and Bim to mitochondria and lyso-
somes, respectively. These steps trigger organellar 
membrane permeabilization necessary to activate execu-
tioner caspases and induce cell death. Thus, analysis of 
Pacs2 loss may not adequately determine whether it is a 
driver or passenger in CRC. Such a conclusion awaits 
gene replacement studies that separate the complex anti- 
and pro-apoptotic roles for PACS-2 in maintaining cell 




1.   Aslan  JE,  et  al.  Mol  Cell.  2009;  34:497–509. 
https://doi.org/10.1016/j.molcel.2009.04.011 
2.   Li  BQ,  et  al.  PLoS  One.  2013;  8:e63494. 
https://doi.org/10.1371/journal.pone.0063494 





5.   Srivatsa  S,  et  al.  Gastroenterology.  2017;  153:178–
190.e10. https://doi.org/10.1053/j.gastro.2017.03.053 








www.aging‐us.com                   1190                                                                             AGING






Keywords:  PACS‐2,  colorectal  cancer,  EGFR,  ADAM17, 
apoptosis  
Funding:  M.K.  is  supported  by  grants  from  the  Danish 
Cancer  Society  and  G.T.  is  supported  by  NIH  grants 
DK114855 and DK112844 
Copyright: Kveiborg  and  Thomas.  This  is an  open‐access 
article  distributed  under  the  terms  of  the  Creative 
Commons Attribution  License  (CC BY  3.0), which  permits 
unrestricted  use,  distribution,  and  reproduction  in  any 






www.aging‐us.com                   1191                                                                              AGING
